BSW Wealth Partners Increases Holdings in Pfizer Inc. (NYSE:PFE)

BSW Wealth Partners increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 32.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 70,209 shares of the biopharmaceutical company's stock after purchasing an additional 17,274 shares during the period. BSW Wealth Partners' holdings in Pfizer were worth $1,779,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer in the fourth quarter worth $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.2%

PFE stock traded down $0.04 during mid-day trading on Friday, hitting $24.20. 39,502,107 shares of the company were exchanged, compared to its average volume of 41,339,880. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $137.56 billion, a P/E ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57. The business has a fifty day simple moving average of $23.46 and a 200-day simple moving average of $24.85. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the business posted $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.11%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PFE shares. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.